Abstract

The invention provides stable controlled release monolithic coating compositions for use in coating pharmaceutical oral dosage forms comprising a 5 polyglycol having a melting point greater than 55°C and an aqueous dispersion of a neutral ester copolymer lacking functional groups.

IPC Classes  ?

• A61K 9/28 - DrageesCoated pills or tablets

Abstract

A controlled release pharmaceutical composition comprises (a) topiramate or a pharmaceutically acceptable salt thereof, (b) a first intelligent polymer component; and (c) a second intelligent polymer component having opposite wettability characteristics to the first intelligent polymer component. The polymer components are effective for controlled release of the pharmaceutically active substance from the composition.

IPC Classes  ?

• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom

Abstract

Polymorphous and amorphous forms of bupropion hydrobromide are described.

IPC Classes  ?

• C07C 225/06 - Compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly-bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and acyclic
• A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone

Abstract

The present invention relates to a pharmaceutical composition comprising a tablet core comprising a combination of actives selected from the group consisting of bupropion hydrochloride and escitalopram oxalate, bupropion hydrobromide and citalopram hydrochloride, bupropion hydrobromide and escitalopram oxalate, and bupropion hydrobromide and quetiapine fumarate, and at least one pharmaceutically acceptable excipient, and a control-releasing coat surrounding the tablet core, wherein said composition surprisingly provides for a synchronous release of the combination of active agents in-vitro. The once-daily pharmaceutical composition surprisingly also provides for enhanced absorption of bupropion hydrobromide when administered to a subject in need of such administration.

IPC Classes  ?

• A61K 9/32 - Organic coatings containing solid synthetic polymers
• A61K 9/36 - Organic coatings containing carbohydrates or derivatives thereof
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• A61K 31/554 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem

Abstract

Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described.

IPC Classes  ?

• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/28 - DrageesCoated pills or tablets

Abstract

Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described.

IPC Classes  ?

• A61K 9/28 - DrageesCoated pills or tablets
• A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
• A61K 33/00 - Medicinal preparations containing inorganic active ingredients

Abstract

An improved controlled release dosage form for once-daily administration of carvedilol is described. The controlled release dosage form comprises a therapeutically effective amount of carvedilol and/or a pharmaceutically acceptable salt thereof; one or more hydrophilic polymers; one or more pharmaceutically acceptable excipients; and a polyoxyalkylene block copolymer, a solid dispersion of carvedilol and an extrusion material or a combination of a polyoxyalkylene block copolymer, a solid dispersion of carvedilol and an extrusion material.

IPC Classes  ?

• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole

Abstract

The invention relates to a pharmaceutical composition, comprising at least one micropartide comprising at least one core which is at least partially coated with at least one osmotic subcoat, and at least one outer coat which at least partially coats the at least one osmotic subcoat, wherein said at least one core comprises at least one drug, and at least one excipient, and said at least one osmotic subcoat comprises at least one osmotic agent and at least one osmotic deposition vehicle.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/50 - Microcapsules

Abstract

The present invention relates to specific types of controlled and modified release dosage forms containing tramadol or at least one pharmaceutically acceptable salt, enantiomer, or metabolite- thereof, that possess specific pharmacokinetic properties and which desirably are not subject to dose dumping, e.g., induced by food or alcohol. The invention also relate to methods of making and using these controlled and modified release dosage forms in therapeutic regimens wherein tramadol is therapeutically effective.

IPC Classes  ?

• A01N 33/02 - AminesQuaternary ammonium compounds
• A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone

Abstract

The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.

IPC Classes  ?

• A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
• C07C 221/00 - Preparation of compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton
• C07C 225/10 - Compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly-bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings with doubly-bound oxygen atoms bound to carbon atoms not being part of rings
• C07C 225/16 - Compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly-bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings

Abstract

The present invention relates to a modified release composition of at least one form of venlafaxine, which is a delayed controlled release composition. The composition comprises a core comprising at least one form of venlafaxine selected from the group consisting of venlafaxine, an active metabolite of venlafaxine, a pharmaceutically acceptable salt of venlafaxine, a pharmaceutically acceptable salt of an active metabolite of venlafaxine, and combinations thereof, less than 10% of a gelling agent and a pharmaceutically acceptable excipient. The composition further comprises a modified release coating which substantially surrounds the core which provides a delayed controlled release of the at least one form of venlafaxine.

IPC Classes  ?

• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/22 - Sustained or differential release type
• A61K 9/24 - Layered or laminated unitary dosage forms
• A61K 9/28 - DrageesCoated pills or tablets
• A61K 9/30 - Organic coatings
• A61K 9/36 - Organic coatings containing carbohydrates or derivatives thereof